ERBB2 and breast carcinoma: Les-6287, Les-6294, and Les-6328 compounds demonstrated high metabolic inhibitory activity towards breast carcinoma MCF-7, T-47D, MDA-MB-231, 4T1, and HCC1954 cells of different types (estrogen and progesterone receptor-positive, triple-negative, and HER2-positive, respectively; Figure 2, Table 2).